Objective. To develop and validate a model of a clinical trial that evaluates the changes in cholesterol level as a surrogate marker for lipodystrophy in HIV subjects under alternative antiretroviral regimes, i.e., treatment with Protease Inhibitors vs. a combination of nevirapine and other antiretroviral drugs.
Introduction
Randomized clinical trials are performed to compare the effect of a new treatment with a control treatment (existing treatment or placebo). The overall objective of the clinical trial is to predict the effect of treatment on the whole population. These trials can be viewed as a physical (real) model aiming to assess the valid result of an experiment [1, 2] , on subjects with very restrictive selection criteria and treated in experimental conditions [3] . However, in many cases, the true effect of treatment is not assessed in practice due to low external validity of the experiment results [4] . Similarly, simulation models of clinical trials are mathematical models viewed as a virtual representation of a clinical trial aiming to describe the evolution or changes of all or some of the variables of interest at particular points in time. In addition to estimating the results, these models are used for analysis, hypothesis testing, research planning and prediction of the evolution and results of treated disease. Constructing these models involves the selection of relevant aspects of the indented objectives, and leaving aside aspects which are considered irrelevant.
These simulation models can be used to retrospectively assess the appropriateness of clinical trial design and to prospectively optimize the design of future trials. They might also help decision-makers to decide whether to continue or discontinue a clinical trial. Models should be validated as part of their development process. Computer simulation has proven a useful tool for model validation and, consequently, for guaranteeing the intended results [5] . From another perspective, simulation models are accepted across disciplines as providing relevant information on the real system. This information can be defined as the adjustment between satisfaction and truth on how the system works [6] . Therefore, when the distance between the simulation model and the truth decreases, satisfaction with the results increases and vice versa.
Two different approaches to validating a model are proposed in the literature: (1) a conceptual validation ensuring that model objectives, structures, and hypotheses are appropriately implemented and make sense to people who have good knowledge of the problem [7] and, (2) a computer model validation that includes model verification, retrospective validation in which model parameters are adjusted to the observed data [7, 8] , and prospective validations that are performed either with concurrent data from simultaneous clinical trials or with future clinical data to predict parameters that model upcoming clinical trials [7] . Retrospective validation, also known as operational validation or results validation [9] [10] [11] , can be subdivided into internal validation and external validation [12] . Internal validation is usually performed when data used to build the model are compared with data generated by the model; while external validation is assessed when the data from other clinical trials are compared to data given by the model [13] [14] [15] . Quantitative comparisons based on hypothesis testing (taking in Confidence Intervals) are commonly used to assess operational validation since they allow an objective decision [10] .
Patten [16] developed Markov models with health states to explore the relationships between chronic medical conditions and major depression. Simulation was employed in order to validate and select the best model as part of the development process. Data from two Canadian general health surveys were used to construct the model and Monte Carlo simulation was conducted to evaluate it. In an initial model (model 1), incidence and cure rates were simulated using a single transition probability, implementing a Markov chain [17] . The results of the initial model suggested that the probability of cure declined linearly by a set constant amount, and the model was modified in order to incorporate this assumption, thus becoming a Markov process [18] . The results of this model showed the best concordance with the observed data and resulted in a decline from the initial value to 0, which contradicted clinical experience in the sense that a cure is possible. Therefore, the author used an exponential equation for the recovery decline (model 3). This model also predicts that the decline rate can be higher in the first weeks and lower later on. The model was extended by substituting a higher recovery probability and maintaining the exponential pattern by reducing the probability to 0 in some model cycles (model 4). Death health state was added to the Markov process and the probability was calculated, converting the 6-year proportion into a weekly transition probability (model 5).
The main objective of this study is to develop, retrospectively validate, and select the best simulation model of a clinical trial that evaluates the changes in cholesterol level as a surrogate marker for lipodystrophy (distribution of body fat) in HIV subjects under alternative antiretroviral regimes, i.e., treatment with Protease Inhibitors vs. a combination of nevirapine with other antiretroviral drugs.
Methods
The development methods of simulation models used in the literature are very similar unless the study-specific aspect is considered. We followed the following steps to construct and validate the models: (1) obtaining the clinical trial protocol and all information on the trial extracted from the protocol, actual experimental data, trial investigators, and expert suggestions; (2) based on the protocol provided and the input of the trial investigator, we developed the conceptual model of the trial including objective, endpoints, structure, and assumptions; (3) the following task was to extract and analyze data in order to make a useful summary of the total cholesterol level to help in construction of the model; (4) we then transformed the conceptual model into mathematical models proposed as good candidates to explain the changes in cholesterol level; (5) we then translated the mathematical model into a computational model using a general modeling and simulation software, Sigma for Windows; (6) we defined the validation and selection criteria; (7) we simulated the model to assure that the expected simulation procedure was working correctly; (8) we simulated the model to estimate and calibrate its parameters; (9) we obtained the standardized distance in mean and variance for all considered endpoints, and (10) we finally selected the best model based on the selection criteria. Fig. 1 shows all these steps and the time (in full days) required for completion of this work. The recursive arrows represent the unit increase in time.
Data
The data used in this paper were part of a larger published randomized clinical trial with HIV subjects approved by the Comité É tico de Investigació n Clínica (CEIC) of the Hospital Universitari Germans Trias i Pujol and conducted at that hospital (a complete description of the trial can be found in Negredo et al. [19] ). As described in that publication, the trial was a prospective, randomized, open-label, 3-arm trial. Subjects who had been receiving a PI-containing regimen and who had long-lasting plasma HIV-1 RNA suppression were randomly assigned either to have the PI replaced by nevirapine or efavirenz, or to continue receiving their previous PI-containing regimen. The main objectives of the trial were to compare the efficacy of the PI-containing regimen and 2 PI-sparing regimens that included nevirapine or efavirenz in maintaining the plasma HIV-1 RNA suppression levels and allowing progressive immunological improvement. Secondary objectives were to assess the impact of PI-sparing regimens on metabolic profile, other adverse events, and quality of life. In addition, variations in body shape in subjects having lipodystrophy at baseline after they began receiving nevirapine or efavirenz instead of a PI was also evaluated, in comparison with subjects who continued to receive PIs. To assess the latter, the authors evaluated the changes in total cholesterol level as a surrogate marker for lipodystrophy. Therefore, data on the subject-based cholesterol level of 49 (PI control treatment, n = 26; new nevirapine treatment, n = 23) were extracted from the overall results of this clinical trial. All subjects had one visit at baseline and four follow-up treatment visits at 3-month intervals thereafter. Only subjects who finished the whole trial were included in the final analysis. Table 1 shows the evolution and relative variations over the course of the four follow-up visits. The clinical trial results show high outcome variability (the last visit cholesterol level) and no statistically significant differences were found between treatments.
The main outcome for estimation of the effect of the treatment was the cholesterol level measured at the last visit. Two-way variance analyses on repeated measures were carried out. The residuals were found to have a normal distribution with a zero mean and standard deviation. This property justifies the inclusion of variability as normal distribution on the models constructed for this clinical trial. Statistically significant differences were found in betweensubjects variability (P < 0.05), but no differences were revealed in within-subjects variability (P = 0.757, P > 0.05).
Both treatments showed similar efficacy when assessed at the last visit, indicating that the new drug combination may not have any statistically significant effect in long-term treatment. Possible reasons could be inappropriate clinical trial design due to erroneous outcome selection for estimation of the effect of the treatment, the fact that the treatment does not work, high variability between subjects due to insufficiently restrictive inclusion or randomized criteria, small sample size, incorrect statistical design or insufficient statistical analysis [4, 20] . Other possible reasons could be flawed selection of study population or wrong dose [21] . Table 2 summarizes the results based on the data obtained in the four follow-up visits. No statistically significant difference was found between the two treatments.
The model
The 2-arm parallel clinical trial can be modeled as the addition of overall mean and variance mixed effects describing cholesterol evolution at discrete points in time [22, 23] . On this basis, formula (1) is introduced as follows:
where y ijT is the cholesterol level in i subject, j visit, and T treatment, where T = {C, N}; j = {0, 1, 2, 3, 4}; l jT is the mean cholesterol level at j visit and T treatment; d i is the between-subjects effect size for i subject; 0 mean and S d standard deviation;e ij is the within-subjects effect size for i subject, at j visit with 0 mean and S e standard deviation. The model allows us to divide the random term into random effect d i presented at baseline visit i (i = 0) and fixed effect with the same value at follow-up visits, and the measurement of random effect, with different values for each follow-up visit including the baseline period. The same concept was applied in order to study sample size requirement and the cost of randomized clinical trial with repeated measurements [4] . Four endpoints were chosen for measuring the size of the treatment effect. The first endpoint quantifies the cholesterol level at the last visit (L, see formula (2)), the second estimates the difference between the last and the baseline visits (D, see formula (3)), the third quantifies the average difference in cholesterol level between the four follow-up visits and the baseline visit (A, see formula (4)), and in order to minimize the overall variability, the fourth endpoint was used to estimate linear changes in cholesterol level from the baseline to the end of the trial, based on the first and last visits (V, see formula (5)).
Five models were developed from the general model based on different assumptions regarding treatment variability and cholesterol reduction patterns over time. The models are described below.
Model 1
The initial model makes the following assumptions in order to estimate input parameters:
and within-subjects effect e ij is random (e i0 " e i1 " Á Á Á " e i4 ); (b) between (S d ) and within-subjects variances (S e ) are equal (S d = S e ); (c) both the new and the control treatment have the same between-subjects variance S d and within-subjects variance S e (S dN = S dC , S eN = S eC ); (d) mean cholesterol level is not the same in the new and control treatments, and its evolution is not constant over time, Table 1) ; and (e) within-subject variance S e remains constant over time (S e0 = S e1 = Á Á Á = S e4 ). This model considers 12 parameters, including mean cholesterol levels.
Model 2
This model replaces model 1 but relaxes the strong assumptions (b) and (c) of model 1 that between and within-subjects variances are equal, and second, are different for each treatment, i.e., in model 2 S dN " S dC and S eN " S eC . The model has 14 parameters.
Model 3
This model is the same as model 2, but relaxes the (e) assumption that within-subjects variance remains constant over time, to allow changes over time according to the expression: , 1, 2, 3, 4}) . The variability changes depend on the Table 1 Cholesterol level changes from the previous visit Table 2 Cholesterol level of all considered endpoints baseline variability. As a result, the rate of change b in variance is constant over time. It was chosen to make this rate close to 1 in order to check if the simulation results changed compared to the previous models. In this model there are 16 parameters.
Model 4
This model modifies model 3 by assuming that the evolution of within-subjects variance follows an exponential equation (S eN = S eN e bj , S eC = S eC e bj , j = {0, 1, ,2, 3, 4}). The rate of change b in variance is considered constant over time. As in the previous model, it was chosen to make this rate h close to 0 in order to check if the simulation results changed compared to the previous models. The model uses 16 parameters.
Model 5
This model replicates model 2 but the changes of within-subjects variance were specified as a time-dependent variance (S e1 " Á Á Á " S e4 ), and between-subjects variance is modified over time according to the rate of change of the variance from the baseline (
. This model permits free evolution of the between and within variability, relaxing the assumptions imposed on models 1, 2, 3, and 4. The model has 28 parameters.
Models were implemented using Sigma for Windows [24] , an appropriate software for discrete events modeling and simulations that focus on these systems where changes in any variable occur at a particular instant in time (such as the clinical trial described here). Sigma for Windows is based on the simple and intuitive event graph approach to simulation modeling. Sigma is an integrated, interactive approach to building, testing, animating, and experimenting with discrete event simulations while they are running. In Sigma, the discrete event system model (clinical trial model) is developed using three elements. These are:
(a) state variables such as cholesterol level function, (b) events that change the value of these variables (i.e., cholesterol level calculation) and (c) relationships between the events, one event causing another to occur (quantification of the cholesterol level in the second period of time after the first level was obtained in the first period).
An event graph organizes sets of these three elements into a simulation model of a clinical trial. In Fig. 2 , events are represented as nodes and the relationships between events as arrows connecting pairs of these nodes (A and B), and representing the condition under which one event will cause another event to occur, after a period of time. Using these concepts, a simulation model of a clinical trial can be built easily and validated while the simulation is running. This software successfully was used for the creation of different models types appeared in the thesis dissertation of the first author [1] .
In Fig. 3 , an event of the clinical trial is represented by seven state variables (nodes) and six arrows (relationships). The Assigning node allows the allocation of treatments considered in the trial; Control and New treatment nodes represent the Protease Inhibitors treatment and the nevirapine treatment, respectively, and five state variables (nodes) were introduced for these two treatments: four related to the follow-up visits (j = 1, 2, 3, 4) while one represents the baseline visit (j = 0) associated to these follow-up visits. The general response variable model represented by Eq. (1) was added to each visit.
Validation and selection
As mentioned before, internal validation is a comparison of the simulation results and those of the clinical trial. The traditional methods for such comparisons are based on hypothesis testing or on the confidence intervals of the means. In our study, we applied a new method of comparison based on the standardized distance, in mean and variance, between real data and simulated data. For any endpoint (L, D, A, V) we defined the standardized distance in mean (SDM) and the standardized distance in variance (SDS) as:
where x o is the observed mean value; S o corresponds to observed standard deviation; x s is the simulated mean value, and S s is the simulated standard deviation of the L, D, A, V endpoints. The first validation criterion is that the standardized distance in means values are 10% minus or plus, as the formula (6) indicates. The second criterion is that the standardized distance in variances are 10% minus or plus, as the (7) indicates. The third criterion is that the model has to reproduce these results simultaneously for all endpoints. Selection of the best model was based on two sequentially applied criteria: (1) the model had to meet the three validation criteria; and (2) the most parsimonious model (i.e., the model containing the lowest number of parameters) fulfilling the previous criteria would be selected. 
Simulation of the clinical trial
One thousand 23 (26) Monte Carlo simulations were run through the mixed effects variance model with initial parameters of mean, S d and S e . The flowchart of the clinical trial simulation model, shown in Fig. 3 , is run as follows.
The simulation started at the Assigning node so as to allow subjects to be allocated parallel to either the control treatment group or the new treatment group. The allocation of the two treatments is based on treatment identification ID (if ID = 0 then subject receives control treatment; if ID = 1 then subject receives the new treatment). Then, at the baseline visit j = 0. The cholesterol level (y ijT ) is quantified from population distribution, applying the baseline mixed variance effects model represented by formula (1) .
This model randomly chooses two values from two normal distributions and sums them to the fixed mean cholesterol level value to obtain the overall cholesterol level [21] . At the first visit (j = 1), the subject's cholesterol level (y ijT ) is updated according to the mean value and the random effect term e ij . The variability d i is fixed and is the same as at the baseline visit, and added to mean cholesterol level and random variability e ij . The calculation is then repeated for the three remaining visits of the clinical trial. The end criterion of the individual simulation is that when a subject completes the last visit (j = 4), s/he exits the model and the next subject enters, and so on until all 23(26) subjects of the control and new treatment, respectively, have been simulated and the last visit of each one of the trial follow-ups complete. This simulation is repeated 1000 times, changing the random seed, thus resetting all model variables to zero. In addition, another series of simulations was run, in which 115(130) subjects were allocated to the control and new treatments, respectively. 
Estimation of model parameters
Estimating the input parameters using calibration with simulation involves selecting the correct parameters to characterize the problem under study. In this study, we use iterative processes to estimate the input parameters until the results of the model meet the validation criteria described in the previous section. Assuming that subjects come from the same population with a common distribution for between and within-subjects variability and that variabilities are mutually independent, the calibration process started by summing up the two components of variability to obtain overall variability at the last visit (j = 4), as shown in the following formula:
where S total is the result of summing the two variabilities. Using this formula, it was easy to develop a model based only on the results for the L endpoint. However, when other endpoints had to be considered, simulation for each of the models was employed. Parameter calibration of between and within-subjects variability of all the models depended on the observed total variability of the last visit. The total variability was decomposed into two equal variabilities (between and within-subjects variances). In order to calibrate the models that best adjusted to the expected results, the distance between these two variances was increased according to a reliability value given as the ratio of the between-subject to overall variability represented by standard deviation (see formula (9) ). This reliability equation was used considering the two variabilities as the square of standard deviation [22] .
First, the reliability value was considered less than 0.5, so that in order to reach the required calibrated model, the distance was increased by reducing the between-subjects variability and raising the within-subjects variability. For each change in the input parameters, a run of 23 and 26 subject simulations-for the new and the control treatments respectively-was performed and repeated 1000 times (r) in order to reduce the difference between upper and lower case the confidence interval of the standardized distance in variance up to 0.002. An additional simulation series was carried out after arbitrarily but proportionately increasing the number of subjects for each repetition to 115 and 130 subjects for the control and new treatments, respectively, in order to reduce the difference between upper and lower case of the confidence interval to 0.001.
Results
First we calculated the results of the first set of simulations arising from repetition of the individual simulation 1000 times. Table 3 shows the summary statistics of these results for all models and endpoints simultaneously. As with the results of the clinical trial, no significant difference between the two treatments is shown in Table 3 . The standardized distance, in means and variance of the simulation models in Table 4 , shows that all five models are within the minus or plus interval for the L, D, and A endpoints. The standardized distance in variance for the V endpoint is only within the minus or plus interval in the case of models 2, 4, and 5. However, the standardized distance trends show that all models are within the 10% minus or plus interval. Model 5, based on the assumption that within-subjects variability of cholesterol levels changes over time, is the one that minimizes the validity criterion, i.e., distance is equal or 1% minus or plus. Table 5 shows the probabilities of success of 1000 repetitions of the simulation for 245 subjects instead of 49. The precision of the estimation is increased by the fact that standard error decreases compared to that of previous results. Consequently, the power of estimation of SDS for all endpoints is much higher (Table 5) . These results also illustrate that model 5 is more efficient, since it has higher success probabilities for all endpoints. If we leave the parsimony criterion aside, this model is the best since it is the one that the best reproduces reality and could therefore be used to assess the design of the clinical trials. Model 2, however, is the best when considering the parsimony criterion.
The model parameters estimated and calibrated by the simulation are shown in Table 6 . All parameters are constant, except S d and b, which correspond to model 5 and vary over the follow-up visits.
Discussion and conclusion
In this research, an innovative approach for the validation and selection of a model for simulation of clinical trials was applied. The mechanism used to estimate parameters, calibrate the models, and validate their results performed very well. Thus, it can be used to estimate parameters of simulation models when analytical methods do not exist or are difficult to apply. Five simulation models based on data for subjects completing the clinical trial were constructed, and an operational internal validation was carried out against the data used in construction of the model. Monte Carlo simulation was used based on two approaches: population simulation and clinical trial simulation. The first simulated a large number of subjects (10,000) and repeated the runs/simulations for different sets of parameters in order to quantify uncertainty. The second approach simulated the population approach and repeated it many times (1000) in order to quantify variability between repetitions. The number of such repetitions depended on the desired level of precision (SE = 0.05). These methods can be applied to evaluate discrete state variables [25, 26] and continuous state variables [27] , as other authors have done in similar contexts [28] . The approach to model construction was similar to that of Patten [16] , but differed in using mixed variance effects statistical models to represent continuous variable health states. The rationale for using this type of modeling was the nature and quantity of the data obtained from the clinical trial. Health states were represented by the level of cholesterol and linked by the logical relationships shown in Fig. 2 . We evaluated them using Monte Carlo simulation in order to estimate the model's results. Like Patten, our models were based on data collected from only one clinical trial, and may therefore not be generalizable to other populations. Simulation can, however, be used to transfer the findings to other contexts by adjusting the parameters, structures, and assumptions as required.
The simulation models allowed relaxation of the strong assumptions in model parameters; however, this implies the addition of further parameters to the model. Hence, for models 1, 2, 3, 4, and 5 the number of parameters rises to 12, 14, 16, 16 , and 28, respectively. Simulation also permits calibration of models with complex parameter combinations, such as in model 5. These results demonstrate that model 2 meets the selection criteria; therefore we can assume that this model is the best for optimization purposes. Model 5 minimizes the validation criterion to be equal to or 1% minus or plus. This model is the most efficient since it has the highest success probability for all endpoints simultaneously (Table 5 , success probability > 0.9). However, it is not convenient for certain applications, since there are many parameters that need to be simultaneously specified and calibration may therefore be problematic. In any case, the problem can be solved by considering parameter optimization through simulation (i.e., assigning intervals of values to each input parameter and simulating all possible combinations to find the optimal input parameters). To perform that, the use of a supercomputer is strongly recommended in order to generate large number of simulations at minimum time. This mechanism for parameter estimation can be applied to any given mixed variance model. We found that the variability of the main clinical trial outcome was very high (Table 3) . For example, the pooled standard error according to model 2 was 12.31. Contrasting that result with the result of the trial, the simulation model was able to determine that there was a low probability of success in obtaining significant results with the trial. Therefore, the simulation models would suggest not proceeding. This problem might be caused by an error in outcome definition, i.e., if the trial results were based on the average changes from baseline (endpoint A in Table 4 ), the success probability of the modeled trial could be increased by simulating more subjects. This information is useful in answering clinical questions such as: what is the most efficient endpoint for the clinical trial?
Performing operational validation (results validation) might be sufficient in order to assess validated conceptual models and validated computer models. Nevertheless, one question remains unanswered: what should the cut-point be for the model goodness of fit (10% or 1%?) in order to be confident that it will reproduce future clinical trial data. Therefore, validation and selection can consider additional criteria, such as relative capacity of prediction between models. This criterion can only be applied if we validate the model with other data. Alternatively, this can be done by constructing the model with retrospective data and carrying out sensitivity analysis in order to approximate it to the proposed clinical trial, as some authors have done [20] . For instance, Monte Carlo simulation was used to evaluate a survival model to validate it and estimate the effects of treatments [29] . The simulated survival curve was compared to the observed curve. Other authors proposed collecting data from clinical trials and other sources in order to calibrate and validate any model with prediction purposes [2, 30] .
In summary, simulation, as a rule, is used to refine clinical trial models in estimating and calibrating their parameters, and help decision makers in evaluation of their study results. Model validation by simulation under standardized distance in mean and variance is an innovative approach, and might be extended to other purposes, such as the assessment of efficacy, safety, and equivalence of treatments in clinical trials. For example, it could be applied to calculate the success probability of not finding differences between two treatments under equal variability. 
